Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Haemophilia Foundation Australia’s post on LinkedIn, adding:
“Hemostasis is far more than the cessation of bleeding – it is a finely regulated biological equilibrium between procoagulant and anticoagulant mechanisms.
Disruption of this balance may manifest as either hemorrhagic complications or thrombotic disease, emphasizing the complexity of modern hemostasis.
Contemporary research increasingly highlights the intimate interplay between coagulation, inflammation, endothelial function, and immune responses, giving rise to the concept of immunothrombosis and reinforcing the multidisciplinary nature of thrombosis research.
These advances continue to reshape diagnostic algorithms, risk stratification, and therapeutic strategies across numerous clinical disciplines.
Continuous scientific collaboration, evidence-based practice, and translational research remain fundamental to improving outcomes for patients with bleeding and thrombotic disorders.”
Haemophilia Foundation Australia shared a post on LinkedIn:
“Currently most gene therapy for haemophilia uses gene transfer.
This involves delivering a functional gene into the body using a vector that carries it into the target cells.
This vector is often a modified virus called adeno-associated virus (AAV) made safe to use.
Once inside the body, the working gene gives instructions to liver cells to produce the missing clotting factor, which may reduce or stop bleeding episodes (‘bleeds’).
Learn more in the new Gene Therapy fact sheet.
Gene therapy is currently only available in Australia through clinical trials.
Gene therapy for haemophilia B is currently being evaluated by the Australian Government for funding to become available for Australians and we look forward to the outcome.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 14:30Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’
-
Jun 29, 2026, 13:01Edward Lee Carter: Exploring Anticoagulation Paradox
-
Jun 29, 2026, 12:55Salvatore Massimo Petrina: When is it Truly Safe to Stop Anticoagulation after AF Ablation?